Here are three things to know.
1. Austedo is intended to treat chorea — an involuntary movement disorder — associated with Huntington’s. Ninety percent of patients with the disease experience chorea.
2. The drug represents the second FDA-approved treatment for Huntington’s.
3. Teva said the drug will be available in the next three weeks.
More articles on supply chain:
11 drugs on FDA’s new safety alert list
How SSM Health’s pharmacy concierge program helps patients manage high drug costs
Sanofi agrees to pay $20M for overcharging VA for vaccines: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.